

EXPRESS MAIL NO.: EV475143057US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Kinch, Michael S.	Confirmation No.:	2188
Application No.:	10/565,771	Art Unit:	To Be Assigned
Filed:	January 23, 2006	Examiner:	To Be Assigned
For:	DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS	Attorney Docket No.:	10271-131-999

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the United States Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to references **A01-A11**, **B01-B06** and **C01-C23** listed on the attached revised PTO-1449 Form entitled "List of References Cited by Applicants." Copies of **B01-B06** and **C01-C23** are submitted concurrently herewith.

Copies of references A01-A11 are not submitted herewith because they are U.S. patents, patent publications and pending applications that have been stored in the IFW system of United States Patent and Trademark Office. Pursuant to 37 C.F.R. §1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

Identification of the listed references is not to be construed an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. §1.97 (b)(3), Applicant estimates that no fee is due in connection with the filing of this Information Disclosure Statement. However, should the Patent Office determine otherwise, please charge the necessary fee to Jones Day Deposit Account No. 50-3013.

Date: August 25, 2006

Respectfully submitted,



Margaret B. Brivanlou

JONES DAY

222 East 41st Street

New York, New York 10017

(212) 326-3939

40,922

(Reg. No.)

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 10271-131-999	APPLICATION NO. 10/565,771
	APPLICANT Michael S. Kinch	
	FILING DATE January 23, 2006	ART UNIT To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	5,416,192	05/16/95	Shoyab et al.	
	A02	4,474,893	10/02/84	Reading	
	A03	4,714,681	12/22/87	Reading	
	A04	4,925,648	05/15/90	Hansen et al.	
	A05	5,573,920	11/12/96	Randle	
	A06	5,601,819	02/11/97	Wong et al.	
	A07	6,309,826	10/30/01	Serrero	
	A08	6,670,183	12/30/03	Serrero	
	A09	6,720,159	04/13/04	Serrero	
	A10	2003/0108950	06/12/03	Serrero	
	A11	2005/0175616	08/11/05	Kiener et al.	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	WO 91/003060	03/07/91	The Furukawa Electric Co., Ltd		
	B02	WO 92/04793	03/19/92	Minnesota Mining and Manufacturing Company		
	B03	WO 92/08802	5/29/92	Cetus Corporation		
	B04	WO 93/17715	9/16/93	Board of Regents, University of Texas System		
	B05	WO 98/52607	11/26/98	Serrero, G.		
	B06	WO 05/000207	01/06/05	MedImmune, Inc.		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C01	BATEMAN et al., 1990, "Granulins, a novel class of peptide from leukocytes" Biochem. Biophys. Res. Commun. 173(3):1161-8	
	C02	BOSTWICK, 1996, "Progression of prostatic intraepithelial neoplasia to early invasive adenocarcinoma" Eur Urol. 30(2): 145-52	
	C03	BRANCH et al., 2000, "A good antisense Molecule is Hard to Find." Trends Biochem Sci.. 23:45-50	

EXAMINER
NYJD-1609831v2

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD: 1609831.2

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)ATTY. DOCKET NO.
10271-131-999APPLICATION NO.
10/565,771APPLICANT
Michael S. KinchFILING DATE
January 23, 2006ART UNIT
To Be Assigned**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C04	BRAWER, 1999, "Prostate-specific antigen: current status." CA A Cancer Journal for Clinicians 49(5): 264-81	
	C05	CARLES-KINCH et al., 2002, "Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior." Cancer Res. 62: 2840-7	
	C06	CHENG et al., 1996, "Expression of E-cadherin in primary and metastatic prostate cancer" Am. J. Pathol. 148(5): 1375-80	
	C07	CROOKE et al., 1998, "Basic Principles of Antisense Therapeutics." Chapter 1:1-50	
	C08	GENBANK ACCESSION NO. NM_002087, "Homo sapiens granulin (GRN), transcript variant 1, mRNA"	
	C09	GENBANK ACCESSION NO. AY124489, "Homo sapiens PC cell-derived growth factor (GRN) mRNA, complete cds"	
	C10	GENBANK ACCESSION NO. BC049368, "Homo sapiens TYRO3 protein tyrosine kinase, mRNA (cDNA clone MGC:57186 IMAGE:4821587), complete cds"	
	C11	GENBANK ACCESSION NO. BC051756, "Homo sapiens TYRO3 protein tyrosine kinase, mRNA (cDNA clone MGC:51900 IMAGE:6095596), complete cds"	
	C12	GENBANK ACCESSION NO. M75161, "H.sapiens granulin mRNA, complete cds"	
	C13	GENBANK ACCESSION NO. NM_006293, "Homo sapiens TYRO3 protein tyrosine kinase (TYRO3), mRNA"	
	C14	GREEN et al., 2000, "Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Diseases" Vol. 91:93-105	
	C15	JEN et al., 2000, "Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies." Stem Cells. 8:307-319	
	C16	JIANG et al., 2002, "Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma" Am. J. Pathol. 160: 667-71	
	C17	KOSTELNY et al., 1992, "Formation of a bispecific antibody by the use of leucine zippers" J. Immunol. 148(5):1547-1553	
	C18	OESTERLING, 1991, "Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate." J. of Urol., 145(5): 907-23	
	C19	PAN et al., 2004, "PC cell-derived growth factor expression in prostatic intraepithelial neoplasia and prostatic adenocarcinoma." Clin. Canc. Res. 10:1333-1337	
	C20	PLOWMAN et al., 1992, "The epithelin precursor encodes two proteins with opposing activities on epithelial cell growth" J. Biol. Chem. 267(18): 13073-8	
	C21	TUTT et al., 1991, "Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells." J. Immunol. 147(1):60-69	
	C22	ZANTEK et al., 1999, "E-cadherin regulates the function of the EphA2 receptor tyrosine kinase" Cell Growth Diff. 10(9): 629-38	
	C23	ZHOU et al., 1993, "Purification of an autocrine growth factor homologous with mouse epithelin precursor from a highly tumorigenic cell line" J. Biol. Chem. 268(15): 10863-9	

EXAMINER
NYJD-1609831v2**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYJD: 1609831.2